Pituitary Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major pituitary disorders markets are expected to exhibit a CAGR of 6.32% during 2024-2034.
The pituitary disorders market has been comprehensively analyzed in IMARC's new report titled "Pituitary Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Pituitary disorders refer to medical conditions that affect the pituitary gland, a small organ situated at the base of the brain that produces and regulates several important hormones. This gland plays a crucial role in controlling various bodily processes, including growth, metabolism, reproduction, function of other endocrine glands, etc. When pituitary disorders occur, they can disrupt the normal production and regulation of hormones, leading to a range of symptoms and potential complications, like visual disturbances or growth abnormalities. The common indications of these illnesses include persistent or severe headaches, fatigue, weakness, unexplained changes in weight, increased thirst and urination, alterations in appetite, sexual dysfunction, irregular or absent menstrual periods in women, infertility, reduced libido, etc. The diagnosis of the disorders involves a combination of medical history evaluation, clinical feature review, and physical examination. Numerous imaging techniques, like magnetic resonance imaging (MRI) or computed tomography (CT) scans, are recommended to visualize the pituitary gland's structure and identify any abnormalities, such as tumors or cysts. Furthermore, genetic testing may be performed to determine the underlying causes of the indications.
The rising cases of benign tumors, which can impair the production and release of hormones due to the compression of normal tissues, are primarily driving the pituitary disorders market. In addition to this, the increasing incidence of head injuries or trauma that can damage the pituitary gland and disrupt its normal function is creating a positive outlook for the market. Moreover, the widespread adoption of hormone replacement therapy to alleviate symptoms associated with hormone deficiencies as well as promote muscle strength, energy, and bone health is further bolstering the market growth. Apart from this, the inflating application of transsphenoidal procedures, since they involve accessing the pituitary gland through the nasal passage or a small incision in the upper lip, thereby providing a minimally invasive alternative to traditional open surgery, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of targeted therapies that are designed to specifically act on the underlying molecular pathways or genetic mutations responsible for the development and progression of the ailments is expected to drive the pituitary disorders market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the pituitary disorders market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for pituitary disorders and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the pituitary disorders market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the pituitary disorders market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the pituitary disorders market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current pituitary disorders marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the pituitary disorders market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the pituitary disorders market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the pituitary disorders market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of pituitary disorders across the seven major markets?
What is the number of prevalent cases (2018-2034) of pituitary disorders by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of pituitary disorders by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of pituitary disorders by type across the seven major markets?
How many patients are diagnosed (2018-2034) with pituitary disorders across the seven major markets?
What is the size of the pituitary disorders patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of pituitary disorders?
What will be the growth rate of patients across the seven major markets?
Pituitary Disorders: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for pituitary disorders drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the pituitary disorders market?
What are the key regulatory events related to the pituitary disorders market?
What is the structure of clinical trial landscape by status related to the pituitary disorders market?
What is the structure of clinical trial landscape by phase related to the pituitary disorders market?
What is the structure of clinical trial landscape by route of administration related to the pituitary disorders market?
The pituitary disorders market has been comprehensively analyzed in IMARC's new report titled "Pituitary Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Pituitary disorders refer to medical conditions that affect the pituitary gland, a small organ situated at the base of the brain that produces and regulates several important hormones. This gland plays a crucial role in controlling various bodily processes, including growth, metabolism, reproduction, function of other endocrine glands, etc. When pituitary disorders occur, they can disrupt the normal production and regulation of hormones, leading to a range of symptoms and potential complications, like visual disturbances or growth abnormalities. The common indications of these illnesses include persistent or severe headaches, fatigue, weakness, unexplained changes in weight, increased thirst and urination, alterations in appetite, sexual dysfunction, irregular or absent menstrual periods in women, infertility, reduced libido, etc. The diagnosis of the disorders involves a combination of medical history evaluation, clinical feature review, and physical examination. Numerous imaging techniques, like magnetic resonance imaging (MRI) or computed tomography (CT) scans, are recommended to visualize the pituitary gland's structure and identify any abnormalities, such as tumors or cysts. Furthermore, genetic testing may be performed to determine the underlying causes of the indications.
The rising cases of benign tumors, which can impair the production and release of hormones due to the compression of normal tissues, are primarily driving the pituitary disorders market. In addition to this, the increasing incidence of head injuries or trauma that can damage the pituitary gland and disrupt its normal function is creating a positive outlook for the market. Moreover, the widespread adoption of hormone replacement therapy to alleviate symptoms associated with hormone deficiencies as well as promote muscle strength, energy, and bone health is further bolstering the market growth. Apart from this, the inflating application of transsphenoidal procedures, since they involve accessing the pituitary gland through the nasal passage or a small incision in the upper lip, thereby providing a minimally invasive alternative to traditional open surgery, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of targeted therapies that are designed to specifically act on the underlying molecular pathways or genetic mutations responsible for the development and progression of the ailments is expected to drive the pituitary disorders market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the pituitary disorders market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for pituitary disorders and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the pituitary disorders market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the pituitary disorders market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the pituitary disorders market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current pituitary disorders marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the pituitary disorders market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the pituitary disorders market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the pituitary disorders market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of pituitary disorders across the seven major markets?
What is the number of prevalent cases (2018-2034) of pituitary disorders by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of pituitary disorders by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of pituitary disorders by type across the seven major markets?
How many patients are diagnosed (2018-2034) with pituitary disorders across the seven major markets?
What is the size of the pituitary disorders patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of pituitary disorders?
What will be the growth rate of patients across the seven major markets?
Pituitary Disorders: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for pituitary disorders drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the pituitary disorders market?
What are the key regulatory events related to the pituitary disorders market?
What is the structure of clinical trial landscape by status related to the pituitary disorders market?
What is the structure of clinical trial landscape by phase related to the pituitary disorders market?
What is the structure of clinical trial landscape by route of administration related to the pituitary disorders market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PITUITARY DISORDERS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PITUITARY DISORDERS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PITUITARY DISORDERS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Epidemiology by Type (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Epidemiology by Type (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Epidemiology by Type (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Epidemiology by Type (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Epidemiology by Type (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Epidemiology by Type (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Epidemiology by Type (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Epidemiology by Type (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)
8 PITUITARY DISORDERS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PITUITARY DISORDERS - UNMET NEEDS
10 PITUITARY DISORDERS - KEY ENDPOINTS OF TREATMENT
11 PITUITARY DISORDERS - MARKETED PRODUCTS
11.1 List of Pituitary Disorders Marketed Drugs Across the Top 7 Markets
11.1.1 Sandostatin LAR Depot (Octreotide) - Novartis
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Somatuline Depot (Lanreotide) - Ipsen
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Isturisa (Osilodrostat) - Recordati
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Recorlev (Levoketoconazole) - Strongbridge Biopharma
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Humatrope (Somatropin) - Eli Lilly and Company
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 PITUITARY DISORDERS - PIPELINE DRUGS
12.1 List of Pituitary Disorders Pipeline Drugs Across the Top 7 Markets
12.1.1 LUM 201 - Lumos Pharma/Merck
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 CRN04894 - Crinetics Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 SPI 62 - Sparrow Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Paltusotine - Crinetics Pharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 CAM 2029 - Camurus
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. PITUITARY DISORDERS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PITUITARY DISORDERS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PITUITARY DISORDERS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Pituitary Disorders - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Pituitary Disorders - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Pituitary Disorders - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Pituitary Disorders - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Pituitary Disorders - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Pituitary Disorders - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Pituitary Disorders - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Pituitary Disorders - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Pituitary Disorders - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Pituitary Disorders - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Pituitary Disorders - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Pituitary Disorders - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Pituitary Disorders - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Pituitary Disorders - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Pituitary Disorders - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Pituitary Disorders - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Pituitary Disorders - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Pituitary Disorders - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Pituitary Disorders - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Pituitary Disorders - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Pituitary Disorders - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Pituitary Disorders - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Pituitary Disorders - Access and Reimbursement Overview
16 PITUITARY DISORDERS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PITUITARY DISORDERS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PITUITARY DISORDERS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PITUITARY DISORDERS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PITUITARY DISORDERS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PITUITARY DISORDERS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Epidemiology by Type (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Epidemiology by Type (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Epidemiology by Type (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Epidemiology by Type (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Epidemiology by Type (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Epidemiology by Type (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Epidemiology by Type (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Epidemiology by Type (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)
8 PITUITARY DISORDERS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PITUITARY DISORDERS - UNMET NEEDS
10 PITUITARY DISORDERS - KEY ENDPOINTS OF TREATMENT
11 PITUITARY DISORDERS - MARKETED PRODUCTS
11.1 List of Pituitary Disorders Marketed Drugs Across the Top 7 Markets
11.1.1 Sandostatin LAR Depot (Octreotide) - Novartis
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Somatuline Depot (Lanreotide) - Ipsen
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Isturisa (Osilodrostat) - Recordati
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Recorlev (Levoketoconazole) - Strongbridge Biopharma
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Humatrope (Somatropin) - Eli Lilly and Company
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 PITUITARY DISORDERS - PIPELINE DRUGS
12.1 List of Pituitary Disorders Pipeline Drugs Across the Top 7 Markets
12.1.1 LUM 201 - Lumos Pharma/Merck
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 CRN04894 - Crinetics Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 SPI 62 - Sparrow Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Paltusotine - Crinetics Pharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 CAM 2029 - Camurus
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. PITUITARY DISORDERS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PITUITARY DISORDERS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PITUITARY DISORDERS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Pituitary Disorders - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Pituitary Disorders - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Pituitary Disorders - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Pituitary Disorders - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Pituitary Disorders - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Pituitary Disorders - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Pituitary Disorders - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Pituitary Disorders - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Pituitary Disorders - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Pituitary Disorders - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Pituitary Disorders - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Pituitary Disorders - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Pituitary Disorders - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Pituitary Disorders - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Pituitary Disorders - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Pituitary Disorders - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Pituitary Disorders - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Pituitary Disorders - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Pituitary Disorders - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Pituitary Disorders - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Pituitary Disorders - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Pituitary Disorders - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Pituitary Disorders - Access and Reimbursement Overview
16 PITUITARY DISORDERS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PITUITARY DISORDERS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PITUITARY DISORDERS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
